A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy

BMC Medicine

Volumn 5, Issue , 2007, Pages

  Kawano, Hirokazu ^a,b   Komaba, Shintarou ^a,b   Kanamori, Toshihide ^a,b   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Genomidea Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; MITOMYCIN C; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; INOCULATION; LYMPHOCYTE ACTIVATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SENDAI VIRUS; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; CELL CULTURE; COLON TUMOR; DENDRITIC CELL; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; IN VITRO STUDY; METHODOLOGY; VIRUS INACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CISPLATIN; COLONIC NEOPLASMS; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; MALE; MICE; ONCOLYTIC VIROTHERAPY; SENDAI VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VIRUS INACTIVATION;

EID: 35448965200     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-5-28     Document Type: Article

References (26)

1. Russell SJ RNA viruses as virotherapy agents Cancer Gene Ther 2002, 9:961-6. 10.1038/sj.cgt.7700535 12522435
2. McCormick F Cancer-specific viruses and the development of ONYX-015 Cancer Biol Ther 2003, 2:S157-60. 14508094
3. Heise C Sampson-Johannes A Williams A McCormick F Von Hoff DD Kirn DH ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat Med 1997, 3:639-45. 10.1038/nm0697-639 9176490
4. Kurihara T Brough DE Kovesdi I Kufe DW Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen J Clin Invest 2000, 106:763-71. 381391 10995787
5. Wirth T Zender L Schulte B Mundt B Plentz R Rudolph KL Manns M Kubicka S Kuhnel F A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer Cancer Res 2003, 63:3181-8. 12810646
6. Nemunaitis J Cunningham C Tong AW Post L Netto G Paulson AS Rich D Blackburn A Sands B Gibson B Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients Cancer Gene Ther 2003, 10:341-52. 10.1038/sj.cgt.7700585 12719704
7. Hann B Balmain A Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants J Virol 2003, 77:11588-95. 229311 14557644 10.1128/JVI.77.21.11588-11595.2003
8. Kurooka M Kaneda Y Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells Cancer Res 2007, 67:227-36. 10.1158/0008-5472.CAN-06-1615 17210703
9. Kaneda Y Nakajima T Nishikawa T Yamamoto S Ikegami H Suzuki N Nakamura H Morishita R Kotani H Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system Mol Ther 2002, 6:219-26. 10.1006/mthe.2002.0647 12161188
10. Mima H Yamamoto S Ito M Tomoshige R Tabata Y Tamai K Kaneda Y Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector Mol Cancer Ther 2006, 5:1021-8. 10.1158/1535-7163.MCT-05-0352 16648574
11. Steinman RM Mellman I Immunotherapy: Bewitched, bothered, and bewildered no more Science 2004, 305:197-200. 10.1126/science.1099688 15247468
12. Blattman JN Greenberg PD Cancer immunotherapy: A treatment for the masses Science 2004, 305:200-5. 10.1126/science.1100369 15247469
13. Pawelec G Immunotherapy and immunoselection - tumour escape as the final hurdle FEBS Lett 2004, 567:63-6. 10.1016/j.febslet.2004.02.091 15165894
14. Ahmad M Rees RC Ali SA Escape from immunotherapy: Possible mechanisms that influence tumor regression/progression Cancer Immunol Immunother 2004, 53:844-54. 10.1007/s00262-004-0540-x 15197495
15. Staveley-O'Carroll K Sotomayor E Montgomery J Borrello I Hwang L Fein S Pardoll D Levitsky H Induction of antigen-specific T cell anergy: An early event in the course of tumor progression Proc Natl Acad Sci USA 1998, 95:1178-83. 18712 9448305 10.1073/pnas.95.3.1178
16. Wick M Dubey P Koeppen H Siegel CT Fields PE Chen L Bluestone JA Schreiber H Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy J Exp Med 1997, 186:229-38. 10.1084/jem.186.2.229 9221752
17. Steinbrink K Graulich E Kubsch S Knop J Enk AH CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity Blood 2002, 99:2468-76. 10.1182/ blood.V99.7.2468 11895781
18. Banat GA Christ O Cochlovius B Pralle HB Zoller M Tumour-induced suppression of immune response and its correction Cancer Immunol Immunother 2001, 49:573-86. 10.1007/s002620000153 11225988
19. Gardini A Ercolani G Riccobon A Ravaioli M Ridolfi L Flamini E Ridolfi R Grazi GL Cavallari A Amadori D Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis J Surg Oncol 2004, 87:46-52. 10.1002/jso.20066 15221919
20. Smith RE Colangelo L Wieand HS Begovic M Wolmark N Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01 J Natl Cancer Inst 2004, 96:1128-32. 15292384
21. McMillan TJ Hart IR Can cancer chemotherapy enhance the malignant behaviour of tumours? Cancer Metastasis Rev 1987, 6:503-19. 10.1007/ BF00047465 3327630
22. Allen TM Cullis PR Drug delivery systems: Entering the mainstream Science 2004, 303:1818-22. 10.1126/science.1095833 15031496
23. Minko T Dharap SS Pakunlu RI Wang Y Molecular targeting of drug delivery systems to cancer Curr Drug Targets 2004, 5:389-406. 10.2174/ 1389450043345443 15134222
24. Fujihara A Kurooka M Miki T Kaneda Y Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation Cancer Immunology Immunotherapy
25. Kawano H Komaba S Yamasaki T Maeda M Kimura Y Maeda A Kaneda Y New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin Cancer Chemother Pharmacol
26. Ito M Yamamoto S Nimura K Hiraoka K Tamai K Kaneda Y Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin J Gene Med 2005, 7:1044-52. 10.1002/jgm.753 15756713